Samsung Biologics hosts 3rd ESG event with suppliers to drive sustainable value chains
Samsung Biologics today hosted its third Supplier ESG Day, reinforcing collaboration with suppliers to advance sustainable management practices across the biopharmaceutical value chain. As global regulatory requirements and stakeholder expectations around ESG performance continue to rise, supply chain engagement has become increasingly critical for companies operating in highly regulated industries such as biopharmaceuticals.
Held virtually to enable wider accessibility, this year’s event brought together over 70 companies, demonstrating continued commitment among supplier partners in strengthening ESG capabilities and preparedness.
During the session, Samsung Biologics shared updates on its ESG strategy, including progress toward its net-zero target and ongoing initiatives to enhance supply chain transparency and resilience. With supply chain due diligence becoming key focus areas across global healthcare markets, the company also introduced practical guidance to support suppliers in strengthening ESG governance and aligning with evolving regulatory expectations.
“As sustainability standards continue to evolve across the global healthcare industry, collaboration across the supply chain remains essential,” said Jeongjae Ahn, Senior Director, Head of Sustainable Business Team. “Through continued engagement with our partners, we aim to contribute to building more sustainable and resilient value chains.”
Supplier ESG Day is part of Samsung Biologics’ broader efforts to integrate sustainability across its operations and ecosystem. The company will continue to engage with suppliers through structured communication channels and ESG capacity-building initiatives, to support long-term decarbonization and responsible growth.
Samsung Biologics today hosted its third Supplier ESG Day, reinforcing collaboration with suppliers to advance sustainable management practices across the biopharmaceutical value chain. As global regulatory requirements and stakeholder expectations around ESG performance continue to rise, supply chain engagement has become increasingly critical for companies operating in highly regulated industries such as biopharmaceuticals.
Held virtually to enable wider accessibility, this year’s event brought together over 70 companies, demonstrating continued commitment among supplier partners in strengthening ESG capabilities and preparedness.
During the session, Samsung Biologics shared updates on its ESG strategy, including progress toward its net-zero target and ongoing initiatives to enhance supply chain transparency and resilience. With supply chain due diligence becoming key focus areas across global healthcare markets, the company also introduced practical guidance to support suppliers in strengthening ESG governance and aligning with evolving regulatory expectations.
“As sustainability standards continue to evolve across the global healthcare industry, collaboration across the supply chain remains essential,” said Jeongjae Ahn, Senior Director, Head of Sustainable Business Team. “Through continued engagement with our partners, we aim to contribute to building more sustainable and resilient value chains.”
Supplier ESG Day is part of Samsung Biologics’ broader efforts to integrate sustainability across its operations and ecosystem. The company will continue to engage with suppliers through structured communication channels and ESG capacity-building initiatives, to support long-term decarbonization and responsible growth.
Share article
Related Content